SMC2 and glioblastoma: Of note, the neurodifferentiating activity of CAPE was not specific to any cell type or species as its treatment resulted in differentiated phenotype in human GOTO neuroblastoma, rat PC12 neuroblastoma, and C6 glioblastoma cell lines.